Quoin Pharmaceuticals Ltd. - news published 176 - readings 1.394

BACK
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Post-Effective Amendment to Registration Statement (Form POS AM)

As filed with the Securities and Exchange Commission on March 28, 2025. Registration No. 333- 277016 Registration No. 333- 266476 Registration No. 333- 269543 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT NO. 333- 277016 UNDER THE SECURITIES ACT OF 1933 AND POST-EFFECTIVE AMENDMENT NO. ...

Continue reading
28.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on March 25, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 25, 2025 at 11:58:27.314 .

Continue reading
25.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and related notes to those statements included in this Annual Report. Our consolidated financial statements have been pr ...

Continue reading
13.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (Form 8-K)

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate acco ...

Continue reading
13.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress. Quoin CEO Michael Myers s ...

Continue reading
13.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on March 06, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 06, 2025 at 13:26:30.273 .

Continue reading
06.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on March 04, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 04, 2025 at 12:50:25.891 .

Continue reading
04.03.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on February 27, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 27, 2025 at 12:34:49.919 .

Continue reading
27.02.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on February 04, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 04, 2025 at 14:07:32.373 .

Continue reading
04.02.2025
Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Quoin Pharmaceuticals Ltd. published this content on January 14, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 14, 2025 at 14:01:29.995 .

Continue reading
14.01.2025